Completed PHASE3 INTERVENTIONAL 2-arm NCT00443235

GEM05 for Patients With Multiple Myeloma More Than 65 Years Old

A National, Open-Label, Multicenter, Randomized, Comparative Phase III Study of Induction Treatment With Melphalan/Prednisone/Velcade Versus Thalidomide / Prednisone / Velcade and Maintenance Treatment With Thalidomide / Velcade Versus Prednisone / Velcade in Untreated Patients With Multiple Myeloma More Than 65 Years Old.

Sponsor: PETHEMA Foundation

Conditions Multiple Myeloma

Interventions Melphalan/Prednisone/Velcade Thalidomide/Prednisone/Velcade

Updated 6 times since 2017 Last updated: Sep 16, 2011 Started: Mar 31, 2005 Primary completion: Mar 31, 2007 Completion: Dec 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Multiple Myeloma and is currently completed. PETHEMA Foundation leads this study, which shows 6 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Mar 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

PETHEMA Foundation

Data source: PETHEMA Foundation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albacete, Spain , Alcorcón, Spain , Badajoz, Spain , Badalona, Spain , Barcelona, Spain , Basurto, Spain , Bilbao, Spain , Castellon, Spain , Ciudad Real, Spain , Cuenca, Spain and 40 more locations